Long-Term Open-Label Extension Study of Oral Levosimendan

Summary

The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) who received TNX-103 in a parent study.

Timeline

Start

2026-03-13

Primary completion

2029-03

Completion

2029-03

Drugs

Indications